Expert oncologist Alex Spira, MD, PhD, FACP, shares his excitement for an upcoming program centered on the MARIPOSA study in advanced NSCLC following the ESMO 2023 annual meeting.
Emerging data in the neoadjuvant setting and the expansion of testing in standard practice have presented questions surrounding screening for and developing strategies from variant information in EGFR-mutated resectable non–small cell lung cancer.
Furmonertinib had efficacy and an acceptable toxicity profile when utilized as adjuvant treatment in EGFR-mutated, stage IA2-IIIA non–small cell lung cancer with high-risk pathological factors who have undergone radical surgery